A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

This trial tests an experimental mRNA-based therapy called mRNA-2808 in people with multiple myeloma (a blood cancer) that has come back or stopped responding to prior treatments. The drug is designed to help the immune system recognize and attack myeloma cells. **You may be eligible if...** - You have relapsed or refractory multiple myeloma - You have previously been treated with a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody - You still have measurable disease (detectable markers in blood, urine, or bone marrow) **You may NOT be eligible if...** - You have not had prior exposure to the required standard treatments - You have conditions that make your myeloma or organ function too unstable - Additional exclusion criteria apply (ask your study team for full details) Talk to your doctor to see if this trial is right for you.